The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH₃COO)Cl₂(NH₃)₂(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake

Table 2

Antiproliferative data (IC₅₀, μM) for Complexes 1–3 obtained after 72 h of treatment. Data in brackets represent the resistance factor, RF = IC₅₀ A2780cisR (cisplatin-resistant)/IC₅₀ A2780 (wild-type), rounded to the nearest unity. Data are the mean ± standard deviation (sd) of at least three replicates.

Compound	IC50 (μM)
	A2780	A2780cisR	NT2-D1	HCT 116	A549	MCF-7	MM98
Cisplatin	0.48 ± 0.12	6.22 ± 1.02 (13)	0.10 ± 0.04	2.30 ± 0.30	3.80 ± 0.70	6.46 ± 0.91	3.20 ± 1.02
1	3.71 ± 1.93	52.11 ± 3.48 (14)	1.44 ± 0.16	22.95 ± 3.89	48.20 ± 27.70	78.10 ± 5.60	>100
2	0.16 ± 0.05	1.02 ± 0.68 (6)	0.21 ± 0.08	1.46 ± 0.02	3.11 ± 0.74	8.86 ± 3.45	3.67 ± 1.32
3	12.10 ± 5.20	>100	4.30 ± 1.13	55.26 ± 1.69	77.98 ± 17.66	>100	>100